Search results
29 wrz 2021 · In this ongoing, double-blind, randomized, placebo-controlled, phase 3 clinical trial, we investigated the safety, vaccine efficacy, and immunogenicity of two doses of AZD1222 as compared with...
6 mar 2021 · report the updated primary efficacy results for the Oxford–AstraZeneca ChAdOx1 nCoV-19 (AZD1222) vaccine from three single-blind, randomised controlled trials in the UK and Brazil and one double-blind study in South Africa.
30 mar 2021 · A new variant of SARS-CoV-2, B.1.1.7, emerged as the dominant cause of COVID-19 disease in the UK from November, 2020. We report a post-hoc analysis of the efficacy of the adenoviral vector vaccine, ChAdOx1 nCoV-19 (AZD1222), against this variant.
31 mar 2021 · The randomized controlled trial conducted across Brazil, UK, and South Africa, confirmed the safety and efficacy of AZD1222 against symptomatic COVID-19 . The AstraZeneca/Oxford COVID-19 vaccine was found to possess similar immunogenicity across all age groups following the booster dose .
8 gru 2020 · Oxford–AstraZeneca COVID-19 vaccine efficacy. 2020 has been a difficult year for all, but has seen 58 vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) be developed and in clinical trials, with some vaccines reportedly having more than 90% efficacy against COVID-19 in clinical trials.
24 mar 2021 · AstraZeneca’s interim trial data suggests that the vaccine is 80% effective at preventing COVID-19 among those aged 65 or older, who made up 20% of trial participants.
22 mar 2021 · Interim analysis of a phase III trial has found that the vaccine produced by Oxford University and AstraZeneca was 79% effective at preventing symptomatic covid-19 and 100% effective at preventing severe disease and admission to hospital.
